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Abstract
The role of the novel costimulatory molecule TIM4 in anti-islet response is unknown. We 
explored TIM4 expression and targeting in Th1 (BALB/c islets into C57BL/6 mice) and Th2 
(BALB/c islets into Tbet−/− C57BL/6 mice) models of anti-islet alloimmune response and in a 
model of anti-islet autoimmune response (diabetes onset in NOD mice). The targeting of TIM4, 
using the monoclonal antibody RMT4-53, promotes islet graft survival in a Th1 model, with 30% 
of the graft surviving in the long-term; islet graft protection appears mediated by a Th1 to Th2 
skewing of the immune response. Differently, in the Th2 model, TIM4 targeting precipitates graft 
rejection by further enhancing the Th2 response. The effect of anti-TIM4 treatment in preventing 
autoimmune diabetes was marginal with only minor Th1 to Th2 skewing. B-cell depletion 
abolished the effect of TIM4 targeting. TIM4 is expressed on human B-cells and is upregulated in 
diabetic and islet-transplanted patients. Our data suggest a model in which TIM4 targeting 
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promotes Th2 response over Th1 via B-cells. The targeting of TIM4 could become a component 
of an immunoregulatory protocol in clinical islet transplantation, aiming at redirecting the immune 
system toward a Th2 response.
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Introduction
Islet transplantation has been shown to be a potentially effective cure for type 1 diabetes 
(T1D) and has been demonstrated to normalize glucose metabolism and halt the 
development of diabetic complications (9,38). Unfortunately, islet graft survival rates 
remain below those of other types of allografts (9,28). Considering the potential advantages 
of islet transplantation on diabetic complications (6,34,39) and the relatively low invasive 
nature of the procedure, much research has focused on increasing the success of islet cell 
transplantation (9,12,29). Although multiple factors have been deemed responsible for the 
failure of islet grafts, the development of the alloimmune response and the recurrence of 
autoimmune diabetes play primary roles. In the allo- and autoimmune responses, the 
reciprocal interaction between costimulatory molecules on T-cells and APCs (e.g. CD40L/
CD40 or CD28/B7.1-2) determines, together with the cytokine environment, the 
differentiation of naïve Th0 cells into Th1, Th2, Th17, and Tregs predominantly (13,18,43), 
thus resulting in acceptance or rejection of the graft and in the onset or avoidance of 
autoimmunity. While the role of Th1 and Th17 cells in promoting allo- and auto-immune 
responses and of Tregs in promoting graft and self tolerance has been clearly assessed 
(30,42,43), the role of Th2 cells remains controversial. Although Th1 to Th2 skewing is 
considered a pivotal marker of graft acceptance, the Th2 response per se has been shown to 
be capable of causing graft rejection (17,25,33,41), and the exact role of the Th2 response in 
islet graft rejection remains unclear. TIM4 is a novel costimulatory molecule and a member 
of the T-cell Immunoglobulin Mucin (TIM) family, and it was recently shown to contribute 
to the development of the Th1 and Th2 responses (16). The TIM family consists of eight 
members in mice (TIM1-TIM8) and three in humans (TIM1, TIM3 and TIM4) (16). TIM1 
and TIM3 are primarily expressed on T-cells, while TIM4 is localized on APCs (20) and 
serves as a ligand for TIM1 (1,22). The TIM1-TIM4 axis appears to provide a positive 
activation signal (20,37), leading to T-cell differentiation and activation, at least in models 
of autoimmunity, allergy and asthma (19). In allotransplantation, the targeting of TIM1 
using an anti-TIM1 mAb has been shown to prolong allograft survival in a murine model of 
cardiac allograft rejection by reducing the Th1 and enhancing the Th2 response (35). 
Furthermore, anti-TIM1 mAb treatment was able to abrogate the Th17 response and to 
prolong allograft survival in a model of Th2/Th17 rejection (46). A recent study suggests 
that the TIM1-TIM4 costimulatory pathway may promote tolerance by expanding a 
population of regulatory B-cells (5). However, the specific role of TIM4 in immune 
activation and in anti-islet allo and autoimmune response is not clearly defined (26,45), and 
TIM4 has been implicated as both an inhibitor (21) and enhancer (23) of the immune 
response. In our study, we investigate the role of TIM4 and its targeting during the allo- and 
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autoimmune anti-islet immune responses, with the aim of developing therapeutic tools to 
prolong the lifespan of exogenous (in the context of islet transplantation) and endogenous 
(in the pathogenesis of autoimmune diabetes) islets.
Materials and Methods
Patients
10 islet-transplanted patients, 10 patients with T1D and 10 healthy controls were enrolled at 
the San Raffaele Scientific Institute with Institutional Review Board approval. Table 1. All 
subjects provided informed consent before study enrolment.
Human islet transplantation and immunosuppression
Islets were isolated from pancreata obtained from multi-organ donors, using a modified 
automated method, and were then purified by centrifugation on a discontinuous gradient as 
previously described (14). Islets were then transplanted intra-hepatically according to ABO 
matching. Islet-transplanted patients received the standard triple immunosuppressive 
regimen: anti-thymoglobulin (Thymoglobulin, Genzyme, Framingham, MA) as induction, 
followed by treatment with FK506 ([Astellas, Deerfield, IL]; target blood levels between 6 
and 8 ng/ml) and/or Cyclosporine ([Novartis, Basel, Switzerland]; target blood level 100 
ng/ml) and/or Rapamycin ([Pfizer, New York, NY]; 8-15 ng/ml) and/or Micophenolate 
([Roche, Basel, Switzerland]; 2g/die) and prednisone ([Bruno Farmaceutici, Italy] 5–10 mg/
day); Cyclosporine drug level was assessed by immunocolorimetric assay (Siemens, 
Munich, Germany), FK506 by liquid chromatography–mass spectrometry (). Steroids were 
tapered and then withdrawn within 6 months post-transplant. C-peptide level was assessed 
by immunofluorimetric assay (Tosoh, Tokyo, Japan); Hba1c level was assessed by high-
performance liquid chromatography (Biorad, Hercules, CA); EIR (exogenous insulin 
requirement) was collected through patient interview.
PBMC from human patients
Peripheral blood mononuclear cells (PBMC) fractions were isolated from 20 ml of whole 
blood by Ficoll (GE Healthcare, Piscataway, NJ) density gradient centrifugation.
Mice
C57BL/6J, BALB/cJ, NOD/ShiLtJ and Tbet−/− mice (on a C57BL/6 background) were 
obtained from Jackson Laboratory and maintained as a breeding colony in our animal 
facility. All mice were cared for and used in accordance with institutional guidelines. 
Protocols were approved by the Harvard Medical School Animal Care and Use Committee.
Islet isolation and transplantation
Pancreatic islets derived from BALB/c donor mice were isolated by collagenase digestion 
followed by density gradient purification, and were handpicked. Islets were transplanted 
under the renal capsule of chemically induced 8-week-old mice (streptozotocin, Sigma-
Aldrich, St. Louis, MO, 250 mg/kg, administered i.p.). Rejection of islet allografts was 
defined by blood glucose measurements > 250 mg/dL on two consecutive days.
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In vivo treatment protocols
Islet-transplanted mice were treated with the anti-TIM4 mAb RMT4-53 (rat Ig2a; Bio X 
Cell; West Lebanon, NH) i.p. at doses of 500 μg on day 0 and 250 μg on days 2, 4, 6, 8, 10. 
For B-cell depletion, C57BL/6 mice were treated with an anti-CD22 monoclonal antibody 
conjugated with calicheamicin (anti-CD22/cal; Wyeth, Madison, NJ) at dose of 160 μg i.p. 
at days 0 and 5 (3). In the diabetes prevention study, 10-week-old female NOD mice were 
treated with RMT4-53 at doses of 500 μg on day 0 and 250 μg on days 2, 4, 6, 8, 10, or were 
left untreated. Treated mice were followed for diabetes onset, as defined by two consecutive 
days of blood glucose measurements > 250 mg/dL (BD Logic glucose meter, BD 
Biosciences, San Jose, CA) .
Islet pathology
Transplanted mice were sacrificed at various time points to obtain histology specimens. 
Kidney sections were stained with hematoxylin (Sigma-Aldrich) and eosin (Sigma-Aldrich) 
(3).
ELISPOT and stimulation assays
In vitro and ex vivo IFN-γ and IL-4 production measurements using ELISPOT assays were 
performed to monitor the alloimmune response (BD Biosciences). C57BL/6 splenocytes 
(1×106) were challenged in the presence of 1×106 BALB/c irradiated splenocytes or 0.5 
μg/ml anti-CD3 Ig/anti-CD28 Ig (BD Biosciences) and were cultured for 24h (IFN-γ) or 48h 
(IL-4) as previously described (41). Spots were counted on an Immunospot analyzer 
(Cellular Technology Ltd., Cleveland, OH). In the autoimmune setting, splenocytes 
extracted from NOD mice were re-challenged with 150 μg/ml of the CD4-restricted peptide 
BDC2.5 (Chi Scientific, Maynard, MA) and 50 μg/ml of the CD8-restricted peptide IGRP 
(Abcam, Cambridge, MA). Bone Marrow derived DCs were generated as previously 
described (7,36). LPS (10 μg/ml) and PMA (50 ng/ml) used in the in vitro culture were 
obtained from Sigma-Aldrich.
Flow cytometry and intracellular cytokine staining
Anti-human CD19 (BD Bioscience) and anti-mouse B220 (BD Bioscience), CD11c 
(eBioscience, San Diego, CA), TIM4 (Biolegend, San Diego, CA), CD4 (BD Bioscience), 
CD25 (eBioscience), CD44 (BD Bioscience), CD40 (BD Bioscience), CD69 (BD 
Bioscience), CD80 (BD Bioscience), CD86 (BD Bioscience), CD62L (BD Bioscience), 
Annexin V (BD Bioscience), 7-AAD (BD Bioscience), IL-17 (eBioscience), and FoxP3 
(eBioscience) were used according to the manufacturer’s recommendations (8). Anti-human 
TIM4 was obtained from Novus Biologicals (Littleton, CO): rabbit polyclonal conjugated to 
FITC for flow application (NBP1-76702F). Flow acquisition was performed on a 
FACSCalibur™ analyzer (Becton Dickinson, San Jose, CA), and data were analyzed using 
FlowJo software version 6.3.2 (Tree Star, Ashland, OR).
Th2 differentiation assay
Naive sorted ABM TCR-Tg CD4+CD25− T cells (Th0) were isolated (CD4+CD25− isolation 
kit, Milteny Biotec, Auburn, CA), and activated for 5 days with 1 μg/ml of plate-bound anti-
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CD3 and anti-CD28 antibodies (BD Biosciences) in presence of the same number of isolated 
(CD19+ isolation kit, Milteny Biotec) BM12 CD19+ B-cells (which are specifically 
recognized by the ABM TCR-Tg T-cells). Cultures were supplemented with 5 ng/ml mIL-4 
(R&D System, Minneapolis, MN) and 1 μg/ml anti-IFN-γ-Ig (BD Bioscience) for Th2 
differentiation. T-cells were the harvested and assessed by RT-PCR (40) for GATA3 
expression (Th2 specific marker) to quantify level of differentiation (43).
Statistical Analyses
Data are expressed as mean±standard error for parametric data and median ± 95% 
confidence interval for non-parametric data. Kaplan-Meier analysis was used for survival 
analysis. When groups were compared cross-sectionally, the two-sided unpaired Student t-
test (for parametric data) or the Mann-Whitney test (for non-parametric data) was used 
according to value distribution. In the comparison of 3 or more groups, after assessing 
normal distribution, ANOVA test was performed followed by post hoc T-test with 
Bonferroni correction. A P value of less than 0.05 (by two-tailed testing) was considered an 
indicator of statistical significance. Data were analyzed with a SPSS statistical package for 
Windows (SPSS Inc., Chicago, IL). Graphs were generated using GraphPad Prism version 
5.0 (GraphPad Software, San Diego, CA).
Results
TIM4 expression in vitro: the percentage of TIM4+ B-cells decreases during T-cell 
stimulation in the allo- and autoimmune settings
We first analyzed TIM4 expression on APCs [B-cells and dendritic cells (DCs)] during 
polyclonal T-cell stimulation in both a non-autoimmune setting to mimic the alloimmune 
response and during islet peptide-mediated T-cell stimulation to mimic the anti-islet 
autoimmune response. During polyclonal T-cell stimulation, splenocytes from C57BL/6 
mice were challenged with 0.5 μg/ml anti-CD3 Ig and anti-CD28 Ig for 1 or 2 days, and 
FACS analysis was performed; a reduced percentage of B-cells positive for TIM4 (Figure 
1A) and of DCs positive for TIM4 (Figure 1B) was observed. The expression level of the 
other costimulatory molecules assessed was also modified on B-cells and DCs by anti-CD3-
Ig and anti-CD28-Ig-mediated stimulation, confirming active modulation of these cells. In 
particular, a reduced percentage of B-cells positive for CD40 or CD80 was observed after 
stimulation (Figure 1C), while the percentage of B-cells positive for CD86 or CD69 was 
increased (Figure 1C). To assess if the reduced percentage of TIM4+ B-cells was due to a 
relatively higher level of apoptosis in TIM4+ cells, we compared the level of apoptosis in 
TIM4+ and TIM4− cells after the stimulation. No difference was observed (Figure 1D). We 
thus hypothesize that the reduced percentage of TIM4+ cells after stimulation was due to the 
downregulation of TIM4 following T-cells-mediated transactivation. To assess that, we 
purified B-cells from splenocytes and we cultured them in presence of anti-CD40 for 1 day 
to mimic an interaction with activated CD40L+ T-cells. A reduction in TIM4+ B-cells was 
observed (Figure 1E). To assess if TIM4 dowregulation is a common feature following B-
cells activation, we cultured B-cells in presence of LPS. A consistent reduction in TIM4 
expression was observed (Figure 1E). PMA-mediated stimulation of B-cells was also 
associated to TIM4 downregulation (data not shown).
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No variation in the percentage of CD40 and CD80 positive DCs cells was observed by anti-
CD3-Ig and anti-CD28-Ig-mediated stimulation, while CD86 and CD69 were found 
increased (Figure 1F). No difference in DCs apoptosis was observed (Figure 1G). A 
reduction in the expression of TIM4 in in vitro generated bone marrow derived DCs cultured 
in presence of LPS or anti-CD40-Ig (Figures 1H). For islet peptide-mediated T-cell 
stimulation, splenocytes extracted from normoglycemic NOD mice were stimulated with 
150 μg/ml BDC2.5 (CD4-restricted) or 50 μg/ml IGRP (CD8-restricted) peptides (4,15). A 
decrease in the percentage of B-cells positive for TIM4 was evident during BDC2.5 
stimulation (Figure 1I) and IGRP stimulation (data not shown). The percentage of CD40 and 
CD80 positive B-cells was also reduced, while stable levels of CD86 and CD69 were 
observed (data not shown). The percentage of DCs positive for TIM4 in the BDC2.5- and 
IGRP-stimulated settings remained stable (Figures 1J and data not shown, respectively). 
Stable levels of CD86 and CD80 were observed, while CD40 and CD69 were increased 
confirming that DCs were activated by peptide stimulus (data not shown). The activation of 
NOD B-cells with anti-CD40-Ig or LPS caused the dowregulation of TIM4 expression, 
while, differently then in C57BL/6 mice (data not shown), no reduction in TIM4 expression 
in DCs was observed. Thus, during both polyclonal antibody and islet peptide stimulation, a 
decrease in the percentage of TIM4+ B-cells is evident. The reduction in TIM4+ B-cells 
looks to be related to dowregulation of the receptor following transactivation of B-cells 
mediated by activated T-cells. TIM4 looks also dowregulated in C57BL/6-derived DCs, 
while is more stable in NOD-derived DCs.
TIM4 expression in vivo: the percentage of TIM4+ B-cells and DCs decreases in the anti-
islet allo- and autoimmune responses
We then analyzed TIM4 expression in vivo during the alloimmune or autoimmune anti-islet 
response. To evaluate TIM4 expression on APCs during the alloimmune anti-islet response, 
we transplanted BALB/c mice islets into streptozotocin-treated C57BL/6 mice (fully 
mismatched), and recipient splenocytes were then harvested at 7 and 14 days after 
transplantation and assessed by flow cytometric analysis. A reduced percentage of B-cells 
positive for TIM4 (Figure 2A), and DCs positive for TIM4 (Figure 2B) was observed during 
the alloimmune response. To evaluate TIM4 expression on APCs during the autoimmune 
anti-islet response, we extracted splenocytes from NOD mice at different stages of disease 
(10-week-old prediabetic mice and >14-week-old hyperglycemic mice), and we then 
analyzed TIM4 expression. The percentage of B-cells positive for TIM4 was found reduced 
in hyperglycemic NOD mice compared to 10-week-old pre-diabetic mice (Figure 2C); an 
increase in the percentage of B-cells positive for TIM4 was observed between 4 and 10-
week-old mice. A similar patter was observed For DCs (Figure 2D). A reduction in TIM4 
expression on B-cells and DCs occurs during the anti-islet alloimmune and, after a 
temporary increase, autoimmune responses.
Targeting TIM4 in vitro: RMT4-53 reduces IFN-γ production in the allo- but not in the 
autoimmune setting
To investigate the effect of TIM4 targeting in islet graft rejection and in the onset of 
autoimmune diabetes, we firstly tested the effect of RMT4-53 (an anti-TIM4 mAb) during 
polyclonal or islet peptide-specific stimulation. Splenocytes obtained from C57BL/6 mice 
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were stimulated with anti-CD3/-CD28 Ig in the presence of RMT4-53 (1, 10, or 100 μg/ml) 
for 24 hours. ELISPOT analysis revealed that 100 μg/ml RMT4-53 reduced the number of 
IFN-γ-producing cells (Th1) (number of IFN-γ-producing spots: RMT4-53-treated=111±15, 
untreated=349±16; n=3; p=0.009; data not shown) and skews the immune response toward a 
Th2 profile (IL-4/IFN-γ ratio: RMT4-53-treated=0.7±0.2, untreated=0.2±0.03; n=3; p=0.02; 
data not shown). In autoimmune-relevant assays (BDC2.5 and IGRP stimulation for 24 
hours), the use of RMT4-53 did not significantly affect the number of IFN-γ- or IL-4-
producing cells nor did it change the IL-4/IFN-γ ratio. TIM4 targeting in vitro with 
RMT4-53 therefore reduces the Th1 and favors the Th2 response in vitro during polyclonal 
but not islet peptide-mediated T-cell stimulation.
Targeting TIM4 in vivo in a model of the Th1-mediated alloimmune anti-islet response: 
RMT4-53 promotes a Th2 over a Th1 response and prolongs islet graft survival
We tested the effect of TIM4 targeting in vivo in a model of the Th1-mediated alloimmune 
anti-islet response. BALB/c islets were transplanted into hyperglycemic C57BL/6 mice, and 
graft survival was evaluated in untreated and RMT4-53-treated mice (500 μg i.p. day 0 and 
250 μg i.p. at days 2, 4, 6, 8, 10). A significant prolongation of graft survival was observed 
in treated mice compared to untreated mice (mean survival time [MST], days: RMT4-53-
treated=19, untreated=13; n=10; p=0.01; Figure 3A). Flow cytometric analysis of 
splenocytes extracted from treated and untreated mice at 14 days after transplantation 
revealed a reduced percentage of B-cells positive for TIM4 (Figure 3B) and DCs positive for 
TIM4 (Figure 3C) in RMT4-53-treated mice The reduction in TIM4+ B-cells and DCs was 
not evident when transplanted mice were treated with anti-TIM1 antibodies. We hypothesize 
that RMT4-53 may have a depleting effect on TIM4+ cells during transplantation. We then 
phenotypically and functionally analyzed the immune system profile of treated and untreated 
mice. ELISPOT analysis of recipient splenocytes challenged with donor antigens revealed 
no significant differences in terms of number of IFN-γ-producing cells between RMT4-53-
treated and untreated mice (Figure 3D), while on the contrary an increase in IL-4-producing 
cells was observed in RMT4-53-treated mice (Figure 3E). The Th2/Th1 ratio (IL-4-/IFN-γ-
producing cells) increased significantly in RMT4-53-treated mice compared to controls 
(Figure 3F). We did not observe any significant differences in the percentages of 
CD4+IL-17+ T-cells and CD4 T effector cells (CD4+CD44highCD62Llow) between 
RMT4-53-treated and untreated mice (Figures 3G and 3H, respectively), while a slight 
reduction in Tregs (CD4+CD25+FoxP3+) was observed in the RMT4-53-treated group 
(Figure 3I). TIM4 targeting in vivo, in a model of the Th1-mediated anti-islet response, 
promotes islet graft survival and is associated with a Th1 to Th2 skewing of the immune 
response.
Targeting TIM4 in vivo in a model of the Th2-mediated alloimmune anti-islet response: 
RMT4-53 exacerbates the Th2 response and precipitates islet graft rejection
We then analyzed the effect of targeting TIM4 with RMT4-53 in a model of the Th2-
mediated alloimmune anti-islet response: BALB/c islets were transplanted into 
streptozotocin-treated Tbet−/− C57BL/6 mice, which are characterized by high Th2 (and 
Th17) and virtually absent Th1 responses (31). Delayed islet graft rejection was observed in 
Tbet−/− mice compared to wild-type (Wt) recipients, with 40% of mice displaying long-term 
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islet graft function (MST: Tbet−/− untreated=19 days; n=10; p=0.008 vs. Wt untreated; 
Figure 4A) and preserved islet morphology (Figure 4B). Splenocytes from Tbet−/− or wild-
type mice were extracted at 14 days after transplantation and were stimulated with donor 
derived-antigens in an ELISPOT assay; an augmented Th2/Th1 ratio was observed in 
Tbet−/− compared to wild-type mice (Figure 4C). We then analyzed the effect of RMT4-53 
treatment in Tbet−/− recipients. RMT4-53 treatment accelerated islet rejection compared to 
untreated Tbet−/− recipients (MST: Tbet−/− RMT4-53-treated=9 days, n=7; p=0.0002 vs. 
Tbet−/− untreated; Figure 4A). In our ELISPOT assay, a further increase in the Th2 anti-islet 
response was observed (Figure 4C). TIM4 targeting in a model of the Th2-mediated 
alloimmune anti-islet response thus precipitates graft rejection and further enhances the Th2 
response.
Targeting TIM4 in vivo does not promote the Th2-mediated anti-islet response in the 
absence of B-cells
We have previously demonstrated that the presence or absence of B-cells during allogeneic 
islet transplantation respectively favors a Th1 or Th2 anti-islet response (3,10). We thus 
evaluated whether the Th2 shift observed with RMT4-53 treatment was dependent upon B-
cells. Depletion of B-cell was achieved with an anti-CD22/cal antibody, and graft survival 
and immune profile were analyzed (3). B-cell-depleted mice experienced a slight delay in 
islet graft rejection (MST: B-cell-depleted=17 days, n=6, p=0.004 vs. untreated; Figures 4D) 
with islet grafts that remained mildly infiltrated at 14 days after transplantation (Figure 4E); 
B-cell-depleted mice also displayed an increased Th2/Th1 ratio (Figure 4F). When B-cell-
depleted mice were treated with RMT4-53, no further enhancement of the Th2/Th1 ratio 
was obtained by RMT4-53 treatment (Figure 4F) nor was any prolongation of graft rejection 
observed (on the contrary, an acceleration was evident) (MST: B-cell-depleted RMT4-53-
treated=11 days, n=3; p=0.002 vs. B-cell-depleted; Figure 4D). These data demonstrate that 
the effect of anti-TIM4 treatment on Th2/Th1 ratio and islet graft protection is dependent 
upon the presence of B-cells.
TIM4+ B-cells are characterized by a low costimulatory molecule expression profile and 
reduced IL-4 production
We investigated if the redirection towards a Th2 response obtained by the blockade of 
TIM4+ B-cells may be justified by the specific differences between TIM4+ and TIM4− B-
cells. We first analyzed costimulatory molecule profile in TIM4+ and TIM4− B-cells 
extracted from C57BL/6 splenocytes. Lower expression in CD40 (Figure 5A), CD80 (Figure 
5B), CD86 (Figure 5C) and CD69 (Figure 5D) was observed in TIM4+ B-cells compared to 
TIM4− B-cells. Cytokine profile is also different in TIM4+ and TIM4− B-cells. The 
percentage of IL-4+ B-cells is severely reduced in TIM4+ B-cells compared to TIM4− B-
cells (Figure 5F), while no difference in IFN-γ production was observed (Figure 5E). IL-4/
IFN-γ ratio is thus consequently higher in the TIM4− B-cells population than in TIM4+ 
(Figure 5G). These results indicate that TIM4− B-cells may be more functional than TIM4+ 
B-cells for Th2 differentiation than TIM4+ B-cells. To further investigate that we 
differentiated naïve Th0 cells towards Th2 in an appropriate cytokine milieu (43) in 
presence of B-cells and presence or absence of RMT4-53. T-cells were then harvested and 
assessed for level of differentiation by the analysis of the Th2-specific marker GATA3. RT-
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PCR analysis showed a higher GATA3 expression levels when RMT4-53 is added to the 
differentiation media (Figure 5H). This data indicate a better Th2 differentiation potential 
for TIM4− over TIM4+ B-cells.
Targeting TIM4 in vivo in a model of the autoimmune anti-islet response: RMT4-53 does 
not promote the Th2 response or delay diabetes onset
The efficacy of TIM4 targeting was then tested in the prevention of diabetes in NOD mice. 
RMT4-53 treatment (500 μg i.p. at day 0 and 250 μg i.p. at days 2, 4, 6, 8, 10 beginning at 
10 weeks of age) was ineffective in delaying diabetes onset (Figure 6A). An increased 
percentage of TIM4-expressing B-cells (Figure 6B), but not of TIM4-expressing DCs 
(Figure 6C) was observed in the spleens of RMT4-53-treated mice compared to untreated 
mice at 14 weeks of age. Analysis using an ELISPOT assay revealed a higher number of 
both IFN-γ- and IL-4-producing cells in splenocytes obtained from RMT4-53-treated mice 
challenged with BDC2.5 peptide (Figures 6D and 6E) and IGRP peptide (Figures 6D and 
6E). An increased Th2/Th1 ratio in RMT4-53-treated mice was observed in response to 
IGRP but not to BDC2.5 peptide (Figure 6F). No significant differences were noted with 
regard to CD4+IL17+ T-cells or Tregs between RMT4-53-treated and untreated mice 
(Figures 6G and 6I), while a slight reduction in CD4 T effector cells was observed in 
RMT4-53-treated mice (Figure 6H). In the autoimmune diabetes model, targeting TIM4 did 
not appear to prevent or delay diabetes onset or to induce a clear Th2 skewing of the 
immune response.
The TIM4+ B-cell population is increased in T1D and islet-transplanted patients
We then sought to examine the TIM4 expression profile by flow cytometry in B-cells 
obtained from islet-transplanted patients and from patients with T1D to determine the 
relevance of TIM4 in humans (Table 1). In healthy controls, TIM4+CD19+ B-cells 
represented approximately 6% of PBMC (Figures 7A and 7E) and 54% of all B-cells. An 
increase in the percentage of TIM4+ B-cells was seen in T1D patients (Figures 7B and 7E); 
a less pronounced increase was also observed in islet-transplanted patients (Figures 7C and 
7E). The percentage of TIM4+ cells was gated according to isotype control staining (Figure 
7D).
Discussion
The finely tuned interactions between costimulatory molecules on APCs and T-cells 
determine the activation or the suppression of allo- and autoimmune responses (11,24). The 
targeting of costimulatory pathways represents an emerging therapeutic opportunity for the 
prevention of graft rejection and development of autoimmunity (18). The most well-studied 
and well-characterized pathways thus far are the CD28/B7.1-2 and the CD40L/CD40 
costimulatory pathways, and the targeting of these has been shown to be efficient in 
preventing both graft rejection and autoimmunity in several animal models (41) and clinical 
settings (27,44). More recently, additional costimulatory pathways have been described (e.g. 
OX40/OX40L and the ICOS/B7h) (2). In our work we evaluated the possible efficacy of 
TIM1-TIM4 pathway targeting, using the monoclonal anti-TIM4-Ig RMT4-53 antibody, in 
preventing anti-islet allo- and autoimmunity.
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TIM4 is expressed on B-cells and DCs and appears downregulated following alloimmune 
and autoimmune anti-islet response. The downregulation of TIM4 seems to be a common 
pattern after cell B-cell activation and was also evident in cell cultured with LPS or anti-
CD40-Ig. The use of RMT4-53 (a mAb targeting TIM4) alleviates the anti-islet alloimmune 
response in C57BL/6 mice and delayed islet graft rejection; the effect seems to be associated 
with a skewing toward a Th2 immunoprofile. On the contrary, treatment with RMT4-53 was 
not shown to prevent diabetes onset in the NOD autoimmune model.
The redirection of the immune system toward a Th2 immunoprofile appears to be mediated 
by B-cells, as no increase in the Th2 response was observed after B-cell depletion in 
RMT4-53-treated or untreated recipients. We have previously demonstrated that the 
presence of B-cells is fundamental for directing the anti-islet alloimmune response toward a 
Th1 profile (3). Our data here demonstrate: (i) B-cell depletion causes Th2 deviation of the 
anti-islet response, (ii) RMT4-53 treatment causes a similar deviation of the anti-islet 
response, (iii) no synergistic or additive effect is observed on the Th2 response when 
combining the two treatments; these observations are compatible with an operative model in 
which the Th2 anti-islet alloimmune response is kept under control by a population of 
TIM4+ B-cells, and the function of these cells is suppressed by either anti-TIM4-Ig or B-cell 
depletion (Figure 8). Compared to TIM4− B-cells in fact TIM4+ B-cells appear less efficient 
in priming Th2 response and particular because a highly reduced expression of IL-4 which is 
fundamental for Th2 response development. Consistently with this model, the reduction of 
TIM4 expression on B-cells after anti-TIM4 treatment in the alloimmune but not the 
autoimmune setting can also contribute to the more evident redirection toward a Th2 profile 
observed in the alloimmune setting. The relative contribution in this model of the blockade 
of the phagocytosis of apoptotic bodies that could be obtained by RMT4-53 needs to be 
further investigated. However it is likely that TIM4 has a role in the redirection of the 
immune system, which is separate and independent by its role as a phagocytic receptor. In 
fact, we do not observe a Th2 redirection of the immune response with RMT4-53 after the 
depletion of B-cells, which have little function in the scavenging of apoptotic bodies. Our 
data also clarify the role of the Th2 response in anti-islet rejection. The switching from a 
Th1 to Th2 response in a model of the Th1-mediated anti-islet response functions in the 
delay of islet graft rejection, possibly due to a reduced rejecting capacity of the Th2 
response. Interestingly, the rejection kinetics observed after TIM4 treatment in the Th1 
model is similar to that which is observed in the genetic model of Th2 islet rejection, 
confirming the mechanism of action of RMT4-53. Conversely, in a model in which the Th2 
response is already prominent, further stimulation of the Th2 response by RMT4-53 
treatment precipitates graft rejection, confirming the potential capacity of Th2 cells in 
mediating islet rejection.
The increase in TIM4+ B-cells observed in islet-transplanted patients and T1D patients 
compared to healthy controls could contribute, according to our model, to the decreased 
Th2/Th1 ratio demonstrated in these patients (32). Consistently with the murine model of 
islet transplantation a relatively reduction in TIM4 expression on B-cells is observed in T1D 
patients after transplantation.
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In conclusion, our work demonstrates a significant role for TIM4 and TIM4 targeting in the 
anti-islet alloimmune response, while the role of TIM4 or its blockade in the autoimmune 
response appears to be marginal. TIM4 inhibition may favor the Th2 over the Th1 response, 
and, although in the context of islet transplantation a high Th2 response can still be 
deleterious for the graft, given its reduced anti-graft rejecting capacity, we hypothesize that 
anti-TIM4 treatment could serve as a component of a combination therapy to promote islet 
graft survival.
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During anti-CD3/-CD28 Ig stimulation of splenocytes extracted from C57BL/6 mice, the 
percentage of B-cells positive for TIM4 (B220+TIM4+) (n=3, *p<0.05 and **p<0.01 vs. D0; 
A) and of DCs positive for TIM4 (CD11c+TIM4+) decreases over time (n=3, *p<0.05 vs. 
D0; B). A reduction in B-cells positive for CD40 and CD80 and an increase in B-cell 
positive for CD86 and CD69 was also observed at day 2 after stimulation (n=3, *p<0.05, 
**p<0.01, and ***p<0.001 vs. D0; C). No difference in term of apoptosis was observed in 
TIM4+ and TIM4− B-cells at day 2 after stimulation (D). A reduction in the percentage of 
TIM4+ B-cells was observed after anti-CD40-Ig or LPS stimulation of isolated cells (n=3, 
*p<0.05 vs. D0; E). An increase in DCs positive for CD86 and CD69 was also observed at 
day 2 after stimulation (n=3, **p<0.01 vs. D0; F). No difference in term of apoptosis was 
observed in TIM4+ and TIM4− DCs at day 2 after stimulation (G). A reduction in the 
percentage of TIM4+ DCs was observed after anti-CD40-Ig or LPS stimulation of bone 
marrow derived DCs (n=3, *p<0.05 and **p<0.01 vs. D0; H). The percentage of B-cells 
positive for TIM4 decreases over time in splenocytes extracted from NOD mice and 
stimulated with the islet peptides BDC2.5 (n=3, *p<0.05 and **p<0.01 vs. D0; I). The 
percentage of DCs positive for TIM4 remained unchanged in splenocytes extracted from 
NOD mice stimulated with BDC2.5 (J).
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TIM4 expression on APCs was evaluated by flow cytometry during the allo- (A, B) and 
autoimmune (C, D) anti-islet response in vivo. A decrease in the percentage of B-cells 
positive for TIM4 (n=3, **p<0.01 vs. D0; A) and DCs positive for TIM4 (n=3, **p<0.01 vs. 
D0; B) was evident after fully-mismatched islet transplantation of BALB/c islets into 
C57BL/6 recipients. In diabetes prevention studies, a reduction in the percentage of B-cells 
(n=3, **p<0.01 vs. 10wks; C) and DCs (n=3, *p<0.05 vs. 10wks; D) positive for TIM4 was 
observed in hyperglycemic mice.
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The effect of TIM4 targeting with RMT4-53 was evaluated during the alloimmune anti-islet 
response; RMT4-53 treatment induced a prolongation of islet graft survival compared to 
untreated recipients (n=10, *p<0.05 vs. untreated; A). A decrease in the percentage of B-
cells (n=3, *p<0.0 vs. untreated; B) and DCs (n=3, *p<0.05 vs. untreated; C) positive for 
TIM4 was observed 14 days after transplantation in the splenocytes obtained from 
RMT4-53-treated compared to untreated mice. In ELISPOT assays, an increase in the 
number of anti-donor specific IL-4- (n=3, **p<0.01 vs. untreated; E), but not IFN-γ-
producing cells (D), was observed in splenocytes obtained from RMT4-53-treated compared 
to untreated recipients. The Th2/Th1 ratio shows a significant Th2 deviation in RMT4-53-
treated mice (n=3, *p<0.05 vs. untreated; F). The percentage of Th17 (G) and CD4+ T 
effector cells (H) was similar in RMT4-53-treated and untreated mice, while a reduction in 
the percentage of Tregs was observed in RMT4-53-treated compared to untreated mice (n=3, 
*p<0.05 vs. untreated; I).
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The effect of TIM4 targeting with RMT4-53 was tested in a model of the Th2 (and Th17) 
immune response (BALB/c islets into Tbet−/− C57BL/6 mice). A prolongation of islet 
allograft survival was observed in Tbet−/− C57BL/6 compared to wild-type recipients 
(##p<0.01 vs. Wt untreated; A). RMT4-53 treatment in Tbet−/− mice induced an acceleration 
of islet allograft rejection (Tbet−/− RMT4-53-treated ***p<0.001 vs. Tbet−/− untreated; A). 
Pathology of the graft revealed that islets were still preserved at 100 days after 
transplantation in normoglycemic untreated Tbet−/− C57BL/6 mice (B) with only a mild 
infiltrate within the islet graft. An increased Th2/Th1 ratio was demonstrated in Tbet−/− 
recipients challenged with donor-derived splenocytes compared to wild-type recipients (n=3, 
***p<0.001 vs. Wt untreated; C); a further increase was observed in RMT4-53-treated 
Tbet−/− C57BL/6 compared to untreated Tbet−/− C57BL/6 (n=3, #p<0.05 vs. Tbet−/− 
untreated; C). When BALB/c islets were transplanted into B-cell-depleted C57BL/6 mice, 
islet graft survival was prolonged compared to untreated mice (##p<0.01 vs. untreated; D); 
RMT4-53 treatment in B-cell-depleted recipients promoted islet rejection (**p<0.01 vs. B-
cell-depleted; D). In B-cell-depleted mice 14 days after transplantation, graft histology still 
displayed partially preserved islet morphology (E). An increased Th2/Th1 ratio was 
observed in B-cell-depleted recipients compared to undepleted recipients, while no further 
Th2/Th1 increase was observed after RMT4-53 treatment (n=3, *p<0.05 vs. untreated; F).
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The different phenotype of TIM4+ and TIM4- B-cells was evaluated by flow cytometry. 
Reduced CD40 (A), CD80 (B), CD86 (C), CD69 (D) expression was observed in TIM4+ B-
cells. (n=3, *<0.05 and ***p<0.001). No difference in term of IFN-γ positivity was observed 
(E), while IL-4 and IL-4/IFN-γ ratio is highly reduced in TIM4+ B-cells (n=3, *p<0.05; 
**<0.01; F, G). In an in vitro assay, the Th2 generation, assessed by RT-PCR as increase in 
GATA3 expression, was more efficient when Th0 were cultured in presence of B-cells and 
RMT4-53 (n=3, *<0.05 and **p<0.01 vs. Th0, H).
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RMT4-53 treatment was evaluated in diabetes prevention in NOD mice. No effect was 
observed on the onset of diabetes after RMT4-53 treatment (A). An increase in the 
percentage of B-cells (but not of DCs) positive for TIM4 cells was observed in RMT4-53-
treated mice compared to untreated mice (n=3, *p<0.05; B, C). An increase in the number of 
IFN-γ-producing cells was observed in RMT4-53-treated mice during BDC2.5 (n=5, 
*p<0.05 vs. untreated; D) and IGRP challenge (n=5, *p<0.05 vs. untreated; D) compared to 
untreated mice. An increase in the number of IL-4-producing cells was observed as well 
(BDC2.5 peptide: n=5, *p<0.05 vs. untreated; IGRP: n=5, *p<0.05 vs. untreated; E). The 
ratio of Th2/Th1 shows a significant skewing toward a Th2 response only with IGRP 
peptide challenge (n=5, *p<0.05 vs. untreated; F). No effect was observed on the percentage 
of Th17 cells (G), while a slight decrease in the percentage of T effector cells in RMT4-53-
treated compared to untreated mice was observed (n=3, *p<0.05 vs. untreated; H). The 
percentage of Tregs was unchanged (I).
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TIM4 expression in B-cells obtained from T1D patients and islet-transplanted patients was 
evaluated using flow cytometry. An increase of TIM4+ B-cells was observed in T1D 
patients (n=6; *p<0.05 vs. healthy volunteers; B, E) and in islet-transplanted patients (n=10; 
*p<0.05 vs. healthy volunteers; ##p<0.01 vs. T1D; C, E) compared to healthy controls (A). 
TIM4-positive staining was determined according to isotype control staining (D).
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Model of the role of TIM4+ B-cells in the alloimmune response in islet transplantation. 
TIM4 B-cells in normal conditions inhibits the Th2 immune response (A). TIM4 targeting 
with RMT4-53 enhances the Th2 response (B). In the absence of a Th1 response (as in 
Tbet−/− mice), TIM4 still exerts a Th2 inhibitory effect (C), and TIM4 targeting with 
RMT4-53 enhances the Th2 response (D). In the absence of B-cells, an increased Th2 
response is evident due to the lack of TIM4 inhibition (E), and TIM4 targeting with 
RMT4-53 does not further increase Th2 response (F).
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Table 1











Gender (M/F) 7/3 4/6 7/3
Age (years) 40.3±7.7 43.7±6.0 45.3±3.9
T1D (years) - 24.2±8 27.0±8.1
C-peptide (ng/ml) - 0.01±0.3 1.7±0.5
EIR (U/day) - 30±4.2 8.8±2
HbA1c(%) - 8.7±1.1 6.8±1.0
Time from last islet infusion (months) - - 32.6±11.6
Rapamycin+FK506 - - 5/10
FK506+Mycophenolate - - 4/10
Rapamycin+Azathioprine - - 1/10
T1D (type 1 diabetes); EIR (exogenous insulin requirement); HbA1c (glycated hemoglobin).
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